PRECIGEN, INC. Accounts Receivable, Allowance for Credit Loss
PRECIGEN, INC. (PGEN) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-03-25
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2024-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2023-12-31: Accounts Receivable, Allowance for Credit Loss $184.00K.
- 2022-12-31: Accounts Receivable, Allowance for Credit Loss $184.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-25 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-25 |
| 2023-12-31 | $184.00K 10-K · filed 2026-03-25 |
| 2022-12-31 | $184.00K 10-K · filed 2026-03-25 |
| 2020-09-30 | $7.16M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $8.00M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $8.04M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $7.51M 10-Q · filed 2020-11-09 |
| 2018-12-31 | $5.14M 10-K · filed 2019-03-01 |
| 2017-12-31 | $4.63M 10-K · filed 2019-03-01 |
| 2016-12-31 | $3.70M 10-K · filed 2019-03-01 |
| 2015-12-31 | $2.08M 10-K · filed 2019-03-01 |
| 2015-09-30 | $2.02M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $1.44M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $871.00K 10-Q · filed 2015-05-11 |
| 2014-12-31 | $565.00K 10-K · filed 2018-03-01 |
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |